{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T05:49:19Z","timestamp":1777268959467,"version":"3.51.4"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2020206403"],"award-info":[{"award-number":["H2020206403"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antigen escape and PD-L1\/PD-1 axis-mediated immunosuppression in the tumor microenvironment (TME) are the predominant drivers of treatment failure in adult patients with relapsed\/refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL). CD19-targeted CAR-T monotherapy has limited ability to overcome these two core resistance mechanisms, and achieving long-term durable remission remains a critical unmet clinical need in adults with high-risk, chemorefractory B-ALL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is a single-center, retrospective case report of an adult patient with early-relapsed, chemorefractory B-ALL. Two independent CAR-T products were manufactured from the patient\u2019s autologous peripheral blood mononuclear cells (PBMCs): (1) CD19 CAR-T cells containing an anti-CD19 single-chain variable fragment (scFv), a CD28 transmembrane domain, a 4-1BB co-stimulatory domain, and a CD3\u03b6 signaling domain; (2) PD-L1-armored CD22 CAR-T cells containing an anti-CD22 scFv, a CD8 transmembrane domain, a 4-1BB co-stimulatory domain, a CD3\u03b6 signaling domain, and a membrane-tethered anti-PD-L1 scFv for spatially restricted immune checkpoint modulation. The two CAR-T products were co-infused at doses of 5.0\u00d710\n                      <jats:sup>5<\/jats:sup>\n                      cells\/kg (CD19 CAR-T) and 3.1\u00d710\n                      <jats:sup>5<\/jats:sup>\n                      cells\/kg (PD-L1-armored CD22 CAR-T), respectively. We evaluated the feasibility, anti-leukemic efficacy, and long-term safety profile of this regimen as a bridging strategy to allogeneic hematopoietic stem cell transplantation (allo-HSCT). This treatment was administered under an institutional compassionate use program approved by the Ethics Committee of the Second Hospital of Hebei Medical University (approval number: 2017-R207), with written informed consent obtained from the patient prior to all treatment procedures. Comprehensive diagnostic workup for B-ALL was performed using 8-color multiparameter flow cytometry (MFC), conventional G-banding cytogenetic analysis, and multiplex leukemia fusion gene screening. Serial lumbar punctures with triple intrathecal chemotherapy (dexamethasone 5 mg + methotrexate 10 mg + cytarabine 30 mg) were performed throughout the treatment course; no abnormalities were detected in cerebrospinal fluid (CSF) routine, biochemistry, or flow cytometry assays, and no evidence of central nervous system (CNS) leukemia involvement was observed at any time point. This study is a retrospective observational analysis of a single clinical case, not a prospective interventional clinical trial, and thus was exempt from clinical trial registration requirements in accordance with institutional and national regulatory guidelines for retrospective observational studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The patient achieved minimal residual disease (MRD)-negative complete remission (CR) on day 14 post-infusion, as confirmed by 8-color MFC (detection sensitivity: 0.01%) and next-generation sequencing (NGS) of immunoglobulin heavy chain (IGH) gene rearrangements (limit of detection [LOD]: 10\n                      <jats:sup>\u22126<\/jats:sup>\n                      ). Peak\n                      <jats:italic>in vivo<\/jats:italic>\n                      expansion of CAR-T cells was observed on day 10 post-infusion, with CD19 CAR-T cells accounting for 43.25% and CD22 CAR-T cells accounting for 14.58% of circulating CD3\n                      <jats:sup>+<\/jats:sup>\n                      T lymphocytes. Only grade 1 cytokine release syndrome (CRS), per the American Society for Transplantation and Cellular Therapy (ASTCT) consensus criteria, occurred and resolved completely with supportive care; no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Following consolidative allo-HSCT, rapid hematopoietic reconstitution was achieved, with neutrophil engraftment on day +12 and platelet engraftment on day +14, consistent with the median engraftment timeline for haploidentical HSCT at our institution. Complete donor chimerism (99.86%) was confirmed by short tandem repeat (STR) analysis on day +30 post-transplantation. Notably, the patient maintained MRD-negative sustained remission for 7 consecutive years, with no occurrence of acute or chronic graft-versus-host disease (GVHD) or late treatment-related adverse events. Complete immune reconstitution was achieved by 24 months post-transplantation, with sustained functional immune recovery and a Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) total score of 158\/172 at the 7-year follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case report details the clinical course of an adult patient with early-relapsed, chemorefractory B-ALL who achieved 7-year MRD-negative sustained remission after treatment with PD-L1-armored CD19\/CD22 dual-targeted CAR-T cell co-infusion followed by consolidative allo-HSCT. Our preliminary clinical observation demonstrates that this integrated regimen may mitigate antigen escape and immunosuppressive TME-mediated drug resistance, and effectively function as a bridging strategy to allo-HSCT in high-risk patient populations. The 7-year event-free survival (EFS) and sustained disease control observed in this case provide valuable clinical insights for the structural optimization of armored CAR-T constructs and the design of future prospective clinical trials for R\/R B-ALL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1797562","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T05:27:07Z","timestamp":1777267627000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["PD-L1-armored CD19\/CD22 dual-targeted CAR-T cell co-infusion bridging to allogeneic hematopoietic stem cell transplantation achieves 7-year sustained remission in an adult patient with early relapsed, chemorefractory B-cell acute lymphoblastic leukemia: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Huan","family":"Hua","sequence":"first","affiliation":[{"name":"Department of Hematology, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, China"]},{"name":"Hebei Key Laboratory of Hematology","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shupeng","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, China"]},{"name":"Hebei Key Laboratory of Hematology","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinzhi","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, China"]},{"name":"Hebei Key Laboratory of Hematology","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, China"]},{"name":"Hebei Key Laboratory of Hematology","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, China"]},{"name":"Hebei Key Laboratory of Hematology","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengrong","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, China"]},{"name":"Hebei Key Laboratory of Hematology","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, China"]},{"name":"Hebei Key Laboratory of Hematology","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuxu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, China"]},{"name":"Hebei Key Laboratory of Hematology","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-234492","article-title":"The myth of the second remission of acute leukemia in the adult","volume":"121","author":"Forman","year":"2013","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2024.010","article-title":"CAR-T cell therapy in B-cell acute lymphoblastic leukemia","volume":"16","author":"Testa","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1182\/blood-2018-99-113126","article-title":"Early clinical experience of CD19 x CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia","volume":"132","author":"Gardner","year":"2018","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00146","article-title":"Multi targeted CAR-T cell therapies for B-cell Malignancies","volume":"9","author":"Shah","year":"2019","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40364-019-0178-7","article-title":"Cancer biomarkers for targeted therapy","volume":"7","author":"Liu","year":"2019","journal-title":"biomark Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1182\/blood-2018-99-114415","article-title":"A feasibility and safety study of CD19 and CD22 chimeric antigen receptors-modified T cell cocktail for therapy of B cell acute lymphoblastic leukemia","volume":"132","author":"Yang","year":"2018","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2018.10.002","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-019-0746-1","article-title":"Immune checkpoint blockade and CAR-T cell therapy in hematologic Malignancies","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3227","article-title":"Tislelizumab augment the efficacy of CD19\/22 dual-targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B-cell non-Hodgkin lymphoma","volume":"42","author":"Zhang","year":"2024","journal-title":"Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.63","article-title":"GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade","volume":"24","author":"Gargett","year":"2016","journal-title":"Mol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00262-021-03009-z","article-title":"Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia","volume":"71","author":"Zhang","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0604-3","article-title":"The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia","volume":"54","author":"Jacoby","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.10.011","article-title":"Factors impacting overall and event-free survival following post-chimeric antigen receptor T cell consolidative hematopoietic stem cell transplantation","volume":"28","author":"Molina","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16339","article-title":"Post-chimeric antigen receptor T-cell therapy hematopoietic stem cell transplantation for 52 cases with refractory\/relapsed B-cell acute lymphoblastic leukemia","volume":"189","author":"Zhang","year":"2020","journal-title":"Br J Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70168","article-title":"A phase 2 trial of a \"sandwich\" strategy: sequential CD22\/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"131","author":"Qian","year":"2025","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12967-023-04019-4","article-title":"Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy","volume":"21","author":"Li","year":"2023","journal-title":"J Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0867","article-title":"Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1598754","article-title":"Combined umbilical cord blood and peripheral blood stem cell transplantation with donor lymphocyte infusion for R\/R AML post CAR-CLL1 failure","volume":"16","author":"Meng","year":"2025","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.02.006","article-title":"Sequential allogeneic HSCT after CAR-T therapy for relapsed\/refractory acute lymphoblastic leukemia patients: a long-term follow-up result","volume":"78","author":"Yang","year":"2025","journal-title":"J Adv Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.05.021","article-title":"Efficacy and risk of donor-derived CAR-T treatment of relapsed B-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation","volume":"26","author":"Deng","year":"2024","journal-title":"Cytotherapy"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0926-1","article-title":"Low toxicity and favorable overall survival in relapsed\/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant","volume":"55","author":"Fabrizio","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.934442","article-title":"Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005701","article-title":"Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory B-ALL","volume":"11","author":"Song","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.782785","article-title":"Allogeneic hematopoietic stem cell transplantation for children with acute lymphoblastic leukemia: shifting indications in the era of immunotherapy","volume":"9","author":"Truong","year":"2021","journal-title":"Front Pediatr"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.06.011","article-title":"Debate: transplant is still necessary in the era of targeted cellular therapy for acute lymphoblastic leukemia","volume":"20","author":"Khazal","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2021.2005798","article-title":"Engineering novel CD19\/CD22 dual-target CAR-T cells for improved anti-tumor activity","volume":"40","author":"Zeng","year":"2022","journal-title":"Cancer Investig"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107742","article-title":"CD4+CD25+CD127low regulatory T cells associated with the effect of CD19 CAR-T therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"96","author":"Pan","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.728962","article-title":"CD19 CAR-T cells with membrane-bound IL-15 for B-cell acute lymphoblastic leukemia after failure of CD19 and CD22 CAR-T cells: case report","volume":"12","author":"Sun","year":"2021","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s13577-023-00934-2","article-title":"Donor-derived CAR-T therapy improves the survival of relapsed B-ALL after allogeneic transplantation compared with donor lymphocyte infusion","volume":"36","author":"Liang","year":"2023","journal-title":"Hum Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003479","article-title":"Novel CD19 Fast-CAR-T cells vs. CD19 conventional CAR-T cells for the treatment of relapsed\/refractory CD19-positive B-cell acute lymphoblastic leukemia","volume":"138","author":"Tan","year":"2025","journal-title":"Chin Med J"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.605766","article-title":"Integrating CAR T-Cell therapy and transplantation: comparisons of safety and long-term efficacy of allogeneic hematopoietic stem cell transplantation after CAR T-Cell or chemotherapy-based complete remission in B-cell acute lymphoblastic leukemia","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40364-020-00247-8","article-title":"Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia: who? when? why","volume":"8","author":"Jiang","year":"2020","journal-title":"biomark Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.01.011","article-title":"CAR19\/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Yan","year":"2022","journal-title":"Cytotherapy"},{"key":"B44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000531681","article-title":"Quartic CAR-T cell bridging to twice allo-HSCT therapy in a patient with acute lymphoblastic leukemia","volume":"51","author":"Zhang","year":"2024","journal-title":"Transfus Med Hemother"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33937","article-title":"CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory\/relapsed B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"key":"B46","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12967-025-06399-1","article-title":"Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed\/refractory B cell acute lymphoblastic leukemia","volume":"23","author":"Cao","year":"2025","journal-title":"J Transl Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03398-6","article-title":"Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation","volume":"116","author":"Cao","year":"2022","journal-title":"Int J Hematol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1586349","article-title":"Case report: CD19 CAR-T cells derived from recipient of umbilical cord blood transplantation effectively treated relapsed acute lymphoblastic leukemia after UCBT","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.35754\/0234-5730-2024-69-4-474-483","article-title":"Efficacy of anti-CD19 CAR T therapy after bispecific monoclonal antibody (CD19\/CD3) therapy in a patient with relapsed Ph-positive acute lymphoblastic leukemia with a massive extramedullary component","volume":"69","author":"Aleshina","year":"2024","journal-title":"Gematologiya I Transfuziologiya"},{"key":"B50","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-022-00694-6","article-title":"Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study","volume":"12","author":"Yang","year":"2022","journal-title":"Blood Cancer J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1797562\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T05:27:08Z","timestamp":1777267628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1797562\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2026.1797562"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1797562","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"article-number":"1797562"}}